Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) —  NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (“NSCLC”), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response...

MIAMI, FL, May 17, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced it will host a conference call on Monday, May 18, 2026 at 9:00 a.m. Eastern Time to discuss its first quarter 2026 financial results and provide a corporate update. This release corrects a previously issued announcement to reflect updated conference call details. Conference Call Details •  Date: Monday, May 18, 2026 •  Time: 9:00 a.m. Eastern Time •  Participant Dial-In (U.S. Toll-Free): 877-407-9219 / +1 412-652-1274 •  Participant Dial-In (International): +1 412-652-1274 (additional international numbers available at www.incommconferencing.com/international-dial-in) •  Participant Dial-In (Canada Toll-Free): 877-407-9219 / +1 412-652-1274 Webcast...

TORONTO, May 16, 2026 (GLOBE NEWSWIRE) — VVC Exploration Corporation, dba VVC Resources (“VVC” or the “Company”) (TSX-V: VVC and OTCQB: VVCVF) announces that it has applied to the Ontario Securities Commission (the “OSC”), as its principal regulator, for a Management Cease Trade Order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). This application follows an anticipated delay in filing the Company’s audited annual financial statements, management’s discussion and analysis, and related officer certifications for the fiscal year ended January 31, 2026 (collectively, the “Required Filings”), which are due on June 1, 2026. Reason for Anticipated DefaultThe delay in completing the Required Filings is a direct result of recent material corporate...

LONDON, May 16, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE:NVT) (“nVent”), a global leader in electrical connection and protection solutions, today announced that its Board of Directors has approved a 3-year share repurchase program pursuant to which the Company may repurchase up to $500 million of nVent shares effective on July 23, 2026. The program is in addition to nVent’s existing authorization approved in July 2024, which expires July 23, 2027. nVent has approximately $96 million remaining under the July 2024 authorization. As of March 31, 2026, the company had approximately 162 million common shares outstanding. The authorization does not constitute a commitment to repurchase shares. The Company may conduct the repurchases through open market purchases, block trades and unsolicited negotiated transactions, pursuant...

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy Phase 3 head-to-head trial of the high-dose fianlimab combination versus Opdualag® (nivolumab and relatlimab-rmbw) is ongoing TARRYTOWN, N.Y., May 15, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today reviewed results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma. The trial did not reach statistical significance for the primary endpoint of improvement in progression-free...